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 Abstract 
 Objective: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other 
sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combina-
tion regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, es-
pecially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the ef-
ficacy of Gem/Doce in ES.  Methods: A retrospective analysis of the three participating 
institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of 
the participating institutions between 1989 and 2012. Of this group, 17 patients received che-
motherapy.  Results: Patients’ median overall survival (OS) after the beginning of palliative 
chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/
Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 
months for all patients receiving Gem/Doce. The best response was complete remission in 1 
patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line 
treatment showed measurable responses with a median PFS of 9 months.  Conclusions: In this 
retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospec-
tive studies are needed to better assess the effects of this combination drug therapy. 
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 Introduction 
 Being an extremely rare disease, epithelioid sarcoma (ES) shows unique clinical features 
compared to other sarcoma entities, including a high probability of recurrence and lymphatic 
spread  [1–5] . Unfortunately, patients often develop local recurrences, even after a wide 
excision  [6] . Data on the natural course of the disease are limited due to the rarity of ES and 
is mainly based on anecdotal case reports and monoinstitutional series.
 Tumor grade (grade 2 vs. grade 3 according to FNCLCC) and location (classical vs. 
proximal type) are considered to be associated with different outcomes  [7] . Other parameters 
like age, gender, tumor size and vascular invasion have been reported to correlate with prog-
nosis  [8] .
 Observations from a large cohort (441 patients from the SEER database) showed that 
most patients were between 17 and 60 years of age  [9] . Patients with localized disease had a 
much better outcome than patients with regional metastases (5-year survival of 75 vs. 49%). 
None of the patients with distant metastases was alive at 5 years after diagnosis. The 1-year 
survival probability in the population with distant metastases was 46%. In terms of identi-
fying the primary tumor’s location with patient survival probability, patients with deep axial 
lesions fared the worst, while patients with superficial appendicular lesions had the best 
prognosis. Undergoing surgery seemed to be beneficial (5-year survival of 68 vs. 33% for 
those not undergoing surgery). Surgical excision is the treatment of choice for locally confined 
disease. Despite the overall poor prognosis, surgical excision should also extend to the 
regional lymph node metastases if present (22–29% of the patients)  [10–12] . Amputation has 
not been shown to result in a superior outcome in regard to local control and prognosis in 
comparison to a wide resection  [8] . Sentinel node biopsy has been proposed for patients with 
ES, but the results reported in the literature thus far have not been promising  [13, 14] . 
Furthermore, radiotherapy might be able to improve local control  [15] .
 Since many of the patients (26–69%) will eventually relapse locally, develop nodal (44%) 
or grossly metastatic disease (44%)  [1, 16] , effective chemotherapeutic options are urgently 
needed. Until now, no prospective randomized trials have examined the role of systemic 
chemotherapy, and the value of chemotherapy in this disease is still being questioned  [6] . 
Some case series, case reports and retrospective studies reported on the therapeutic benefit 
of anthracyclines, ifosfamide or vinorelbine  [17–19] . There is only one systematic report 
assessing the role of chemotherapy in the presence of distant metastases  [20] . The authors 
conclude that systemic chemotherapy with anthracyclines/ifosfamide provides satisfactory 
palliation in patients with ES, but responses are of short duration. There is an unmet need for 
more effective and novel ES treatment strategies.
 Anthracyclines are considered the standard first-line therapy in the palliative treatment 
of most subtypes of soft tissue sarcoma (STS). Combination regimens using gemcitabine and 
docetaxel (Gem/Doce) have proven to be effective in STS, especially when used in uterine and 
nonuterine leiomyosarcoma  [21–24] , but are formally not approved for STS treatment. Thus 
far, there are no available data on the efficacy of Gem/Doce for ES. Therefore, we performed 
a retrospective analysis of the three participating institutions to investigate the potential 
benefit of Gem/Doce in treating this disease.
 Methods 
 From 1989 to 2012, 28 patients with an ES diagnosis presented at one of the three participating insti-
tutions (University Hospital Greifswald, Sarcoma Center Berlin-Brandenburg and University Hospital 
Dresden). Clinical and histopathologic data were collected by reviewing medical records and were then 
entered in a comprehensive database ( table 1 ). Response was assessed using World Health Organization 
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Median age (range), years 35.0 (18.0 – 57.0)
Sex
Male 21 (75%)
Female 7 (25%)
Site of primary tumor
Upper limb 11 (39.3%)
Lower limb 11 (39.3%)
Trunk 6 (21.4%)
Primary therapy
Resection part of therapy 24 (85.7%)
R0 8 (28.6%)
R1 12 (42.9%)
R2 4 (14.3%)
Second resection (after R1 or R2) 12 (42.9%)
Isolated limb perfusion + resection 3 (10.7%)
CTX part of therapy 5 (17.9%)
Palliative 2 (7.1%)
Neoadjuvant 1 (3.6%)
Adjuvant CTX only 1 (3.6%)
CTX + RTX 3 (10.7%)
CTX (without adjuvant therapy)
1 line 17 (60.7%)
2 lines 10 (35.7%)
3 lines 5 (17.8%)
RTX 8 (28.6%)
Adjuvant RTX 5 (17.9%)
Adjuvant RTX + CTX 3 (10.7%)
Amputation
All 9 (32.1%)
Curative intent 7 (25.0%)
Palliative intent 2 (7.1%)
Site of metastases at diagnosis 8 (28.6%)
Lymph node (regional) 3 (10.7%)
Pulmonary 3 (10.7%)
Skin 1 (3.6%)
Multiple 1 (3.6%)
Site of metastases during course
Lymph node (not regional) 6 (21.4%)
Pulmonary 17 (60.7%)
Skin 5 (17.9%)
Multiple 2 (7.1%)
Hepar 2 (7.1%)
Bone 4 (14.3)
Local relapse 9 (32.1%)
Local relapse without metastases 6 (21.4%)
CTX = Chemotherapy; RTX = radiotherapy.
 Table 1.  Patient characteristics 
(n = 28)
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criteria and Response Evaluation Criteria in Solid Tumors (RECIST) after 2–3 cycles of chemotherapy. 
Radiologic images were not available for all patients and were not reviewed again for this study. Addi-
tionally, we were unable to retrieve some patients’ toxicity data because we had difficulties in obtaining 
patient records dating back from more than 20 years ago from various institutions. The patients’ records 
indicated that data on adverse events and toxicity were not collected in a systematic manner (i.e. according 
to the common toxicity criteria).
 Twenty-four patients underwent primary resection with or without adjuvant chemotherapy. Four 
patients with widely metastatic disease at diagnosis received chemotherapy with palliative intention. One 
patient presented after having R2 resection elsewhere and refused further treatment.
 Nineteen of 24 patients with primary resection eventually developed metastatic disease. Six of these 19 
patients relapsed locally before manifestation of metastatic disease. Only 1 patient developed a local recur-
rence without metastatic disease. He never received chemotherapy. Three patients who initially presented 
with regional nodal metastases died (6, 15 and 43 months from the first presentation). Three patients were 
lost to follow-up.
 Seventeen patients received at least one course of chemotherapy (CTX). Of those, 10 patients received 
second-line therapy and 5 patients also continued with third-line CTX.
 The choice of the chemotherapy regimen and duration of treatment were at the discretion of the 
treating physician. Treatment response was evaluated by magnetic resonance imaging or computed 
tomography. Progression-free survival (PFS) was defined as the time from the start of chemotherapy until 
disease progression or death. Overall survival (OS) was defined as the time from the start of chemotherapy 
until death by any cause. Follow-up data for surviving patients were censored at the time of their last 
presentation at one of our outpatient clinics. The most frequently used regimens were anthracycline (A) ± 
ifosfamide (I) (13 patients) and Gem/Doce (12 patients). A ± I was mainly used as a first-line treatment (8 
patients.), whereas Gem/Doce was applied as a first-line (6 patients), second-line (7 patients) and third-
line (1 patient) therapy ( fig. 1 ). One patient again received Gem/Doce as a second-line treatment after a 
prior very good response as a first-line treatment. All patients receiving Gem/Doce were treated with a 
fixed-dose rate of gemcitabine, as published by Hensley et al.  [24–26] . Other chemotherapeutic agents 
were high-dose ifosfamide, trofosfamide, gemcitabine/cisplatin, cisplatin/dacarbazine or doxorubicin/
dacarbazine.
 Results 
 The median OS of the whole cohort from the time of the first presentation was 65 months. 
The median OS of patients receiving palliative chemotherapy from the time of their first 
presentation was 41 months. The median OS in patients from the beginning of palliative 
chemotherapy was 21 months ( fig. 2 ). Twelve-month OS was 87%.
 Response to Anthracycline or Anthracycline/Ifosfamide 
 In our retrospective analysis, 13 patients received A or A/I (8 patients as a first-line, 1 
patient as a second-line and 4 patients as a third-line treatment) with a clinical benefit rate 
(CBR) of 46% [complete remission (CR) 0, partial remission (PR) 0 and stable disease (SD) 6 
patients]. Irrespective of the treatment line, the median PFS was 3 months in patients treated 
with A, 8 months in patients treated with A/I and 3 months in patients who received other 
regimens (high-dose ifosfamide, trofosfamide, gemcitabine/cisplatin, cisplatin/dacarbazine 
or doxorubicin/dacarbazine).
 Response to Gemcitabine/Docetaxel 
 Twelve patients received a total of 12 combination regimens of Gem/Doce in the course 
of the disease (6 patients first-line, 5 patients second-line and 1 patient third-line treatment). 
Ten of 12 patients had SD or better. This translates into a CBR of 83%. The median PFS was 
8 months in all patients and 9 months in patients treated with Gem/Doce as a first-line 
treatment.
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 Patients responded to Gem/Doce irrespective of the line of treatment. An objective 
response was seen in 7 of 12 regimens of Gem/Doce and in 0 of 13 regimens of A ± I, as illus-
trated in  figure 3 , indicating that the frequency of objective response is significantly higher 
after Gem/Doce (p < 0.05, Fisher’s exact test). Other regimens also did not demonstrate any 
objective response.
 The best response to first-line treatment was CR in 1 patient and PR in 5 patients. The 
best response to second-line treatment was PR (n = 1), and even in the third-line treatment, 
the patient experienced disease stabilization of more than 6 months ( fig. 4 ).
 Classic versus Proximal-Type ES 
 Eight patients with classic ES were treated with Gem/Doce. Best responses were CR (n = 
1), PR (n = 4) and SD (n = 3). Median PFS was 8 months. Four patients with proximal-type ES 
were treated with Gem/Doce. Two patients did not respond to this type of therapy [progres-
sive disease (PD); n = 2], while the remaining 2 patients had PR with a PFS of 8 and 9 months, 
respectively.
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 Discussion 
 Until now, no prospective randomized trial examining the role of systemic chemotherapy 
in ES has been published. Due to the rarity of the disease, the only data available stem from 
some case series, case reports and retrospective studies  [17–19] .
 Anthracyclines are considered the standard first-line chemotherapeutic agent in most 
STS subtypes. The most frequently used regimens in ES include anthracyclines and ifos-
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famide. One of the two available retrospective studies was performed to evaluate the clinical 
features, the management and the outcome of pediatric and adolescent patients with ES  [20] . 
Thirty patients over the age of 18 with ES who were enrolled in the Italian Soft Tissue Sarcoma 
Committee protocols were included. Eight of these 30 patients were treated with systemic 
chemotherapy over the course of their disease (2 patients with anthracyclines but no ifos-
famide, 6 patients with regimens including ifosfamide and anthracyclines). The response to 
primary chemotherapy was evaluable in 7 patients and was CR in 2 patients, PR in 1 patient, 
and SD in 4 patients accounting for an overall response rate of 43%. All 3 patients who 
responded to chemotherapy had received combination regimens including ifosfamide and 
anthracyclines.
 The retrospective study by Jones et al.  [17]  was performed to assess the role of chemo-
therapy for ES patients with distant metastases and, to our knowledge, is the only study to 
address this question that has been published to date. The study reported on 21 patients with 
ES, treated with chemotherapy between 1990 and 2009 at a single referral center. The 
patients’ most commonly chosen regimens were single-agent doxorubicin and doxorubicin in 
combination with ifosfamide. The response to first-line chemotherapy was evaluable in 20 
patients. Three patients had PR, 12 patients SD and 5 patients PD. All objective responses 
were seen in patients with classic-type ES. The median PFS was 29 weeks, and the 6-month 
progression-free rate was 53%. The median OS from commencing palliative chemotherapy 
was 51 weeks, and the 12-month OS probability amounted to 46%.
 The authors concluded that their results, and those of the Italian group reported 
beforehand, suggest that some of the patients with ES benefit from palliative chemotherapy 
with A and A/I.
 In our series, 13 patients received A or A/I (8 patients as a first-line, 1 patient as a second-
line and 4 patients as a third-line treatment) with a CBR of 46% (CR 0, PR 0 and SD 6 patients). 
The median PFS was 8 months across all lines of therapy. Although no patient in our study 
showed an objective response to A or A/I, our data are consistent with the results of the retro-
spective study of Jones et al.  [17]  in terms of the CBR and the median PFS. A relevant propor-
tion of patients in our study (46%) and in the study of Jones et al.  [17]  (75%) achieved at least 
disease stabilization for more than 6 months (median PFS of 8 and 6.6 months, respectively).
 In our analysis, 10 of 17 (59%) patients had at least one further treatment after first-line 
therapy failed, which differs from the study of Jones et al.  [17] , in which only 7 of 21 (33%) 
patients received further treatment after first-line therapy. Furthermore, the best-docu-
mented response in second-line CTX in Jones’ study was SD in 2 patients, lasting 5 and 11 
months, respectively.
 The median OS after the start of palliative chemotherapy in our study was 21 months, the 
1-year OS was 87%. These results suggest that adding Gem/Doce to the treatment plan of 
patients with metastatic ES may have improved the outcome of our patient cohort, especially 
considering that patients in our study receiving Gem/Doce had a median PFS of 8 months. 
However, it should be noted that, given the retrospective nature of our analysis, a selection 
bias cannot be excluded.
 Looking at patients’ response to Gem/Doce across all lines of therapy, we found that 7 of 
12 patients achieved at least a PR, while CBR amounted to 83% (10 of 12 patients). Our study 
indicates a comparable median PFS of 8 months for the advanced ES patients receiving either 
A/I or Gem/Doce. Notably, all 6 patients receiving Gem/Doce as a first-line treatment showed 
measurable responses (median PFS of 9 months) in comparison to the lack of measurable 
responses for the 7 patients treated with the combination regimen of A/I (median PFS of 8 
months).
 Patients with classic ES and with proximal-type ES responded to Gem/Doce. PFS of 
responding patients was comparable in both groups, but the numbers were too small for 
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further conclusions. It is important to note that Gem/Doce is currently not approved for the 
treatment of STS.
 To date, no second-line treatment regimen, following the failure of A/I, has been shown 
to be active in metastatic ES.
 The present study has some limitations. It is important to consider the relatively small 
number of patients in the study when drawing conclusions from the data. Apart from the 
above-mentioned possibility of a selection bias, a radiologic review of response by RECIST 
criteria could not be performed in all patients, so some patients with clinical PR might not 
have met the formal criteria for response. Moreover, patients were treated with Gem/Doce 
across different lines of therapy, which could be another limitation in interpreting the results. 
We were also unable to systematically collect data regarding the toxicity of Gem/Doce and 
patients’ quality of life. The main aim of this study was to investigate the efficacy of Gem/Doce 
in ES, since the adverse events and toxicity profile have been well described in other studies 
 [21, 23–26] . The most frequently occurring adverse events were hematologic, with some 
patients requiring a dose reduction. In our study, there were no treatment discontinuations 
due to toxicity. Clearly, a prospective randomized trial would be able to provide more solid 
data on the efficacy of the regimen. However, given the rarity of the disease, it would be very 
challenging to perform such a study.
 In conclusion, our retrospective analysis not only demonstrates that patients with meta-
static ES benefit from palliative chemotherapy but also that Gem/Doce is a promising chemo-
therapeutic regimen in ES treatment. Adding Gem/Doce to the armamentarium of antiprolif-
erative drugs may improve OS in ES patients with metastatic disease.
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